Summer Waugh
Acute Care · Sugar Land, TXNPI 1437456563
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,702 of the $14,509 with a category attached, or 66.9%. 29 manufacturers reported payments, led by Medtronic at 30.4% of the total. 2025 is the largest year on record at $5,269, 5.4 times the $973 reported in 2021. Among acute care clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 333 payments — averaging $43.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Boston Scientific$4K
- Biosense Webster, Inc.$2K
- Abbott$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$424
- Johnson & Johnson$240
- plus $1K from 23 others
What the payments were for
- Travel & lodging$4,74633%
- Food & beverage$9,70267%
- Education$380%
- Entertainment$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 67 | $4,417 |
| Boston Scientific | 87 | $4,209 |
| Biosense Webster, Inc. | 47 | $2,115 |
| Abbott | 57 | $1,740 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 18 | $424 |
| Johnson & Johnson | 13 | $240 |
| Impulse Dynamics (USA) Inc. | 3 | $214 |
| Altathera Pharmaceuticals LLC | 1 | $157 |
| Baxter Healthcare | 3 | $141 |
| Atricure, Inc. | 4 | $111 |
| Endologix LLC | 3 | $101 |
| Pfizer | 4 | $80 |
| Biotronik Inc. | 2 | $68 |
| Stryker | 2 | $56 |
| Smith+Nephew | 2 | $49 |
| Surmodics, Inc. | 2 | $48 |
| Cvrx, Inc. | 2 | $47 |
| E.r. Squibb & Sons, L.L.C. | 3 | $47 |
| Ossur Americas, Inc. | 2 | $46 |
| Sanofi-aventis U.S. LLC | 2 | $44 |
| La Jolla Pharmaceutical Company | 1 | $26 |
| Argentum Medical | 1 | $22 |
| Kestra Medical Technology Services, Inc. | 1 | $20 |
| Octapharma USA, Inc. | 1 | $20 |
| Biotissue Holdings Inc. | 1 | $20 |
| Angiodynamics, Inc. | 1 | $16 |
| AstraZeneca | 1 | $14 |
| Novo Nordisk | 1 | $13 |
| Lifenet Health | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$1,606
- Carto 3$952
- WATCHMAN FLX$936
- AVEIR$401
- OPTIMIZER$299
- Sotalol Hydrochloride$157
- DURATA$147
- ASSURITY$113
How this compares
$14,509 in reported general payments places this provider in the 95th percentile of 2,323 acute care providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 133 | $118,088 |
| EliquisApixaban | 129 | $105,844 |
| Metoprolol Succinate | 247 | $3,863 |
| Amiodarone Hcl | 77 | $1,529 |
| Flecainide Acetate | 28 | $1,309 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 15 | $1,296 |
| Mexiletine Hcl | 20 | $1,084 |
| ClopidogrelClopidogrel Bisulfate | 102 | $494 |
| Nebivolol Hcl | 12 | $422 |
| Propafenone Hcl | 14 | $398 |
| Digoxin | 20 | $389 |
| Colchicine | 46 | $386 |
| Minocycline Hcl | 55 | $361 |
| SotalolSotalol Hcl | 15 | $240 |
| Carvedilol | 30 | $229 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $240 | $118,088133 claims |
| PfizerEliquis | $80 | $105,844129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,323 acute care providers in Texas.
Other acute care in Sugar Land
- Bahia ElkamandSugar Land$23K
- Alexandra TrudeauSugar Land$12K
- Jennifer PilotteDallas$232K
- Christie MorrisonSan Antonio$225K
- Amanda BradleyDallas$85K
- Laura WilsonEl Paso$32K
- Kim HuynhCypress$29K
- Martha LibertyDallas$28K
- Afton DickersonHouston$27K
- Eleanor WeltgeHouston$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.